Loading…
← CockpitCompetitor Analysis › 7780.T Menicon Co., Ltd.Open in the cockpit ↗

Menicon Co., Ltd.7780.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties
Momentum leader 84
Mkt cap
$944M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$3.86M
20-day average traded
Fwd P/E
20.9×
forward earnings
ROIC−WACC
+0.2 pp
WACC 5.2%
Hurdle
n/a
no reverse DCF
Next earnings
86 days
12 Feb 2027
Close · JPY¥1,973
1D+1.2%
1W+2.2%
1M+4.6%
3M+0.4%
6M+26.5%
YTD+23.5%
1Y+60.9%
ATR %3.3%
52w lowhigh5.4% off high

What Menicon does

Employees: 4,493

Menicon at a glance

Size Menicon (7780.T) is a Japan Health Care company (Medical Specialties) with a market value of $944M, the 766th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,973 on 18 Nov 2026.

Performance Over six months the shares gained 26.5%, against -13.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 5.6% over the last twelve months (peer median +8.4%); the operating margin is 8.7% (peer median 9.6%).

Valuation It trades at 20.9× forward earnings against a peer median of 19.9× (8th most expensive of 16).

Capital Return on invested capital runs 0.2 points above its cost of capital (5.2% WACC).

Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 20267780.T 129Peer median 87
Six months, rebased to 100: Menicon against the median of its 20 peers (local-currency closes).

Menicon financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥129B¥126B¥121B¥116B¥110B
Revenue growth—+3%+5%+5%—
Gross profit¥69.2B¥67.6B¥65.1B¥61.0B¥58.5B
EBITDA¥22.5B¥21.1B¥18.5B¥16.9B¥19.5B
Net income¥6.34B¥5.92B¥5.60B¥4.54B¥7.38B
Free cash flown/a-¥3.37B-¥77.0M-¥8.24B¥1.31B
Capital expendituren/a¥16.5B¥17.5B¥21.3B¥13.0B
Total debt¥78.1B¥74.2B¥75.1B¥70.8B¥53.6B

Quarterly statements and history in the cockpit →

Menicon competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%290650SFL30467730KURN300143AORTCBLLBVS3015803002066885753006856886266523688277301021600055EUZ7780.T6-month return →1-month return →
Up and to the right = strong over both horizons. Menicon is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×SFL30467730KURN300143AORTBVS30158068857568876768862665237780.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Menicon is the large dot.

Menicon competitors and peer comparison

How Menicon compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Menicon against its 20 peers (data as of 18 Nov 2026)
Measure7780.TPeer medianRank in peer set
1-month return+4.6%-7.2%4th highest of 21
6-month return+26.5%-13.6%4th highest of 21
Distance from 52-week high-5.4%-35.6%highest of 21
Revenue growth (TTM)+5.6%+8.4%10th lowest of 21
Operating margin8.7%9.6%10th lowest of 21
Forward P/E20.9×19.9×8th most expensive of 16
ROIC minus cost of capital+0.2 pp+2.8 pp8th lowest of 20
EV / EBITDA8.8×10.3×4th cheapest of 10
Net debt / EBITDA2.1×0.3×3rd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%

Questions

Which companies are Menicon's closest peers?
The cockpit's peer set: L&C BIO (290650.KS), Safilo (SFL.MI), JINS (3046.T), Mani (7730.T), Kuros Biosciences (KURN.SW), INKON Life Technology (300143.SZ), Artivion (AORT), Ceribell (CBLL).
Is Menicon expensive compared with its peers?
On forward p/e it trades at 20.9× against a peer median of 19.9×, 8th most expensive of 16 in its peer set.
How has Menicon stock performed?
Over six months to 18 Nov 2026 the shares returned +26.5% against -13.6% for the median peer; over one year +60.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.